<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309111</url>
  </required_header>
  <id_info>
    <org_study_id>GBR 1342-101</org_study_id>
    <secondary_id>2016-005253-20</secondary_id>
    <nct_id>NCT03309111</nct_id>
  </id_info>
  <brief_title>Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2, First-in-Human, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ichnos Sciences SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ichnos Sciences SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety profile, maximum tolerable dose (MTD)
      and cohort expansion of single-agent GBR 1342 in subjects with multiple myeloma who have
      received prior therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD) of GBR 1342 (Part 1)</measure>
    <time_frame>28 days</time_frame>
    <description>MTD will be assessed by detection of number of DLTs (dose limiting toxicities) during the first 28 days after the first administration of study drug (i.e. Cycle 1) in each cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response to GBR 1342 according to International Myeloma Working Group (IMWG) response criteria (Part 2)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of AEs according to CTCAEv4.03</measure>
    <time_frame>28 days</time_frame>
    <description>The relationship of the dose of GBR 1342 with frequency and severity of AEs will be assessed based on CTCAEv4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of GBR 1342</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve from zero to time t (AUC0-t) of GBR 1342</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of GBR 1342 by anti-drug antibody (ADA) formation assessed from baseline until end of treatment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of GBR 1342 (Disease control rate)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>GBR 1342</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label dose escalation of GBR 1342</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GBR 1342</intervention_name>
    <description>GBR 1342 will be administered by intravenous (IV) infusion on Day 1 and Day 15 of each 28-day treatment cycle at escalating dose levels</description>
    <arm_group_label>GBR 1342</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with progressive or relapsed multiple myeloma (by IMWG) refractory to
             proteasome inhibitors (PIs), immunomodulators (IMiDs) and daratumumab.

          -  Measurable disease, defined as any quantifiable monoclonal protein value

          -  ECOG performance-status score of 2 or less

          -  Life expectancy of at least 3 months

          -  Recovered from any previous surgery and no history of major surgery within the last 28
             days prior to start of study drug

        Exclusion Criteria:

          -  Any condition that, in the opinion of the Investigator, would interfere with
             evaluation of the study drug or interpretation of subject safety or study results.

          -  Active infectious disease considered by the Investigator to be incompatible with the
             protocol.

          -  Evidence of clinically significant cardiovascular and respiratory conditions

          -  Anti-myeloma treatment within 2 weeks

          -  Use of any investigational drug within the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Khazan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ichnos Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ichnos CT Disclosure Desk</last_name>
    <phone>(201) 331-4000</phone>
    <email>clinicaltrialsdisclosuredesk@ichnossciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glenmark Investigational Site 2</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Zengari, MD</last_name>
      <email>mzangari@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 10</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Matous, MD</last_name>
      <email>jeffrey.matous@HealthOneCares.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 3</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Ann Huff, MD</last_name>
      <email>huffca@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Vesole, MD, PhD</last_name>
      <email>david.vesole@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 6</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Richter, MD</last_name>
      <email>Joshua.Richter@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 4</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Smith, MD, PhD</last_name>
      <email>smithe3@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 9</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Berdeja, MD</last_name>
      <email>jberdeja@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 5</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cornell, MD</last_name>
      <email>robert.f.cornell@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 7</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aric Hall, MD</last_name>
      <email>achall@medicine.wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBR 1342 CD38/CD3 Bispecific Antibody</keyword>
  <keyword>GBR 1342 in Previously Treated Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

